Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 1499
Gene Symbol: CTNNB1
CTNNB1
0.090 GeneticVariation disease BEFREE In addition, ovarian and uterine endometrioid adenocarcinomas with beta-catenin defects show a common gene expression signature largely distinct from that seen in tumors lacking such defects. 15788657 2005
Entrez Id: 7157
Gene Symbol: TP53
TP53
0.070 GeneticVariation disease BEFREE In contrast, non-endometrioid adenocarcinomas had a higher frequency of p53 alterations (54%), PIK3CA mRNA overexpression (45%), and exon 20 PIK3CA mutations (21%). 19234438 2009
Entrez Id: 5728
Gene Symbol: PTEN
PTEN
0.050 GeneticVariation disease BEFREE Although the mutation of PTEN, a tumor suppressor, is known to be involved in tumorigenesis of endometrioid adenocarcinomas of the endometrium and ovary, the role of PTEN alteration in endometrioid adenocarcinoma of the cervix remains to be investigated. 15172121 2004
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
0.040 GeneticVariation disease BEFREE These findings support the hypothesis that endometriosis-associated and independent endometrioid adenocarcinoma may develop via different molecular pathways and that KRAS mutations have an important role only in the former tumors. 22305241 2012
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
0.040 GeneticVariation disease BEFREE Since the biologic nature of SECs is unknown, we aimed to study the prevalence of KRAS gene mutations in SECs and the underlying WD endometrioid adenocarcinomas (EC) from which they directly arise. 27154241 2016
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
0.040 GeneticVariation disease BEFREE To explain the pathogenetic significance of endometrial mucinous metaplasia, we analyzed the immunohistochemical expression of ER, PR, MKI67, PTEN, β-catenin, P16(INK4A), TP53, and PAX2 in 21 endometrial mucinous metaplasias, screened for KRAS (n=16) and PTEN (n=14) mutations, and compared expression patterns between samples with simple mucinous glands, those with complex glands having intraglandular papillary tufts, and endometrioid adenocarcinomas. 22766790 2012
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
0.040 GeneticVariation disease BEFREE Confirmed partial responses were observed in patients with BRAF-mutant melanoma (n = 1) and KRAS-mutant endometrioid adenocarcinoma (n = 1). 31020608 2020
Entrez Id: 673
Gene Symbol: BRAF
BRAF
0.030 GeneticVariation disease BEFREE This study hypothesized that the BRAF V600E mutation may be associated with mucinous morphology in endometrial cancer and aimed to investigate its prevalence in mucinous (endometrial) carcinoma (MC) and endometrioid adenocarcinoma with significant mucinous differentiations (ECMD) (>10% neoplastic cells). 23370429 2013
Entrez Id: 673
Gene Symbol: BRAF
BRAF
0.030 GeneticVariation disease BEFREE Confirmed partial responses were observed in patients with BRAF-mutant melanoma (n = 1) and KRAS-mutant endometrioid adenocarcinoma (n = 1). 31020608 2020
Entrez Id: 673
Gene Symbol: BRAF
BRAF
0.030 GeneticVariation disease BEFREE In contrast, BRAF mutations do not appear to have a significant role in either endometrioid adenocarcinoma subgroup. 22305241 2012
Entrez Id: 5290
Gene Symbol: PIK3CA
PIK3CA
0.020 GeneticVariation disease BEFREE In the mixed endometrioid adenocarcinomas-non-endometrioid adenocarcinomas, the most frequent alterations were p53 (50%) and PIK3CA (44%) mutations, followed by PTEN mutations (38%). 19234438 2009
Entrez Id: 8289
Gene Symbol: ARID1A
ARID1A
0.020 GeneticVariation disease BEFREE It has also been suggested that ARID1A mutation occurs at the early stage of canceration from endometriosis to endometriosis‑associated carcinoma in ovarian cancer and also from atypical endometrial hyperplasia to endometrioid adenocarcinoma in endometrial cancer. 26572704 2016
Entrez Id: 3973
Gene Symbol: LHCGR
LHCGR
0.010 GeneticVariation disease BEFREE Our results suggest that SNPs rs2479106 in gene DENND1A and rs13405728 in gene LHCGR are associated with endometrioid adenocarcinoma. 22902918 2012
Entrez Id: 259307
Gene Symbol: IL4I1
IL4I1
0.010 GeneticVariation disease BEFREE Total laparoscopic hysterectomy, bilateral salpingo-oophorectomy, and pelvic lymphadenectomy revealed International Federation of Gynecology and Obstetrics (FIGO) stage II endometrial cancer: a 12-cm grade 3 endometrioid adenocarcinoma with 80% MMI and lymphovascular invasion (LVI) involving the outer half of the cervical stroma ( Fig 1 ), and without pelvic lymph node involvement. 31163010 2019
Entrez Id: 57706
Gene Symbol: DENND1A
DENND1A
0.010 GeneticVariation disease BEFREE Our results suggest that SNPs rs2479106 in gene DENND1A and rs13405728 in gene LHCGR are associated with endometrioid adenocarcinoma. 22902918 2012
Entrez Id: 10436
Gene Symbol: EMG1
EMG1
0.010 GeneticVariation disease BEFREE A total of 250 patients were enrolled, and the concordance rates were 56% for endometrioid adenocarcinoma grade 1 (EMG1), 67% for EMG2, 67% for EMG3, 82% for carcinosarcoma, 71% for serous carcinoma, and 67% for clear cell carcinoma. 30826751 2019
Entrez Id: 1956
Gene Symbol: EGFR
EGFR
0.010 GeneticVariation disease BEFREE EGFR mutations were observed in 27.9% (19/68) in serous adenocarcinomas, 15.0% (3/20) in clear cell adenocarcinomas, and 66.7% (2/3) in mucinous adenocarcinomas, while no mutations were observed in endometrioid adenocarcinomas (0/11). 21057220 2011
Entrez Id: 8205
Gene Symbol: TAM
TAM
0.010 GeneticVariation disease BEFREE Seven patients with tamoxifen-associated endometrial carcinomas (TAM group) and 28 with sporadic endometrioid adenocarcinomas (EMC group) were included in the study. 21547354 2011
Entrez Id: 4360
Gene Symbol: MRC1
MRC1
0.010 GeneticVariation disease BEFREE It has poor prognosis compared with Grade 3 endometrioid adenocarcinoma and is often associated with the loss of mismatch repair (MMR) proteins, which is seen in microsatellite instability (MSI)-type endometrial cancer. 31370215 2019
Entrez Id: 581
Gene Symbol: BAX
BAX
0.010 GeneticVariation disease BEFREE BAX somatic frameshift mutations in endometrioid adenocarcinomas of the endometrium: evidence for a tumor progression role in endometrial carcinomas with microsatellite instability. 9840618 1998
Entrez Id: 5426
Gene Symbol: POLE
POLE
0.010 GeneticVariation disease BEFREE The Cancer Genome Atlas described four major genomic groups of endometrial carcinomas, including a POLE ultramutated subtype comprising ∼10% of endometrioid adenocarcinoma, characterized by POLE exonuclease domain mutations, ultrahigh somatic mutation rates, and favorable outcome. 25394778 2015
Entrez Id: 10232
Gene Symbol: MSLN
MSLN
0.300 Biomarker disease CTD_human Application of mesothelin immunostaining in tumor diagnosis. 14576474 2003
Entrez Id: 1499
Gene Symbol: CTNNB1
CTNNB1
0.090 Biomarker disease BEFREE Diverse mechanisms of beta-catenin deregulation in ovarian endometrioid adenocarcinomas. 11719457 2001
Entrez Id: 1499
Gene Symbol: CTNNB1
CTNNB1
0.090 Biomarker disease BEFREE Consistent with the proposal that beta-catenin is an important regulator of IRS1 expression in vivo, we observed that IRS1 is highly expressed in many cancers with constitutive stabilization of beta-catenin, such as colorectal carcinomas and ovarian endometrioid adenocarcinomas. 19843521 2010
Entrez Id: 1499
Gene Symbol: CTNNB1
CTNNB1
0.090 Biomarker disease BEFREE To explain the pathogenetic significance of endometrial mucinous metaplasia, we analyzed the immunohistochemical expression of ER, PR, MKI67, PTEN, β-catenin, P16(INK4A), TP53, and PAX2 in 21 endometrial mucinous metaplasias, screened for KRAS (n=16) and PTEN (n=14) mutations, and compared expression patterns between samples with simple mucinous glands, those with complex glands having intraglandular papillary tufts, and endometrioid adenocarcinomas. 22766790 2012